Clinical Trials Logo

Lung Metastases clinical trials

View clinical trials related to Lung Metastases.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03108677 Active, not recruiting - Osteosarcoma Clinical Trials

Circulating Exosome RNA in Lung Metastases of Primary High-Grade Osteosarcoma

Start date: May 1, 2017
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to learn whether the profile of RNA from circulating exosomes can be used as a biomarker for lung metastases of primary high-grade osteosarcoma. Circulating exosomes plays roles in metastases in many kinds of cancer including osteosarcoma. By RNA profiling researchers may find lung metastases earlier than conventional work-up and predict the oncological outcomes.

NCT ID: NCT02226276 Active, not recruiting - Clinical trials for HER2-positive Breast Cancer

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Start date: January 7, 2015
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well copper Cu 64-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET) works in predicting response to treatment with ado-trastuzumab emtansine in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread to other places in the body. Copper Cu 64-DOTA-trastuzumab is a chemotherapy drug (trastuzumab) attached to a radioactive substance. Diagnostic procedures using PET may allow scanners to take pictures of where the drug travels in the body and may help doctors identify which patients may benefit from treatment with ado-trastuzumab emtansine.

NCT ID: NCT02107755 Active, not recruiting - Liver Metastases Clinical Trials

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

Start date: July 2, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effectiveness of the combination of stereotactic radiation therapy and ipilimumab in patients with metastatic melanoma that has spread to four or fewer sites in the body (oligometastatic). Stereotactic radiation therapy is a type of external beam radiation therapy that uses special equipment to position the patient and precisely give a either a single large dose of radiation therapy to a tumor or several large doses of radiation therapy to a tumor using precision and accuracy that is guided by onboard daily imaging prior to radiation therapy. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some monoclonal antibodies find tumor cells and help kill them or carry tumor-killing substances to them. Giving stereotactic radiosurgery together with ipilimumab may kill more tumor cells by causing addition melanoma antigens to be presented to the immune system.

NCT ID: NCT01706432 Active, not recruiting - Liver Metastases Clinical Trials

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

Start date: June 15, 2009
Phase:
Study type: Observational

This pilot clinical trial studies new ways to monitor the impact of hypofractionated image guided radiation therapy in treating patients with stage IV breast cancer. Radiation therapy uses high energy x rays to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.